Balance-sheet LeverageModest debt relative to equity (~0.10x) reduces near-term financing strain and provides greater flexibility for a cash-burning biotech. This lowers default risk versus highly leveraged peers and lengthens runway for R&D execution before urgent refinancing needs arise.

Improving Cash Burn TrendOperating and free cash flow remain negative but the meaningful reduction in burn versus 2023–2024 implies tighter cost control or lower spend. A sustained lower burn rate extends the company’s runway and increases odds of reaching clinical milestones before large new financing rounds.

Focused Clinical ProgramA single, clearly defined program (STA363) targeting underlying disc pathology addresses an unmet, structural market need in chronic low back pain. Focused pipelines can concentrate resources, making trial design, regulatory strategy, and eventual commercialization efforts more coherent and durable if clinical efficacy is proven.

Bears Say

Very Limited RevenueAlmost no commercial revenue (TTM 22k) leaves the company fully dependent on financing and R&D success. The lack of diversified revenue streams makes long-term sustainability contingent on trial outcomes and capital markets, increasing binary risk over the next 2–6 months and beyond.

Negative Cash GenerationPersistent negative operating and free cash flow (-6.8M TTM) indicates ongoing cash burn and that operational activities do not cover expenditures. Without durable cash generation, the company will likely require external funding, creating execution and dilution risk that can impair long-term shareholder value.

Shrinking Equity And Negative ROEMaterial equity contraction and very negative ROE (~-103%) reflect accumulated losses and capital erosion. This signals ongoing dilution and financing vulnerability: if losses persist, management will likely need to raise capital, diluting existing shareholders and increasing financial risk over time.

4K4 FAQ

What was Stayble Therapeutics AB’s price range in the past 12 months?

Stayble Therapeutics AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.

What is Stayble Therapeutics AB’s market cap?

Stayble Therapeutics AB’s market cap is €1.16M.

When is Stayble Therapeutics AB’s upcoming earnings report date?

Stayble Therapeutics AB’s upcoming earnings report date is Feb 25, 2026 which is in 7 days.

How were Stayble Therapeutics AB’s earnings last quarter?

Stayble Therapeutics AB released its earnings results on Nov 19, 2025. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is Stayble Therapeutics AB overvalued?

According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Stayble Therapeutics AB pay dividends?

Stayble Therapeutics AB does not currently pay dividends.

What is Stayble Therapeutics AB’s EPS estimate?

Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Stayble Therapeutics AB have?

Stayble Therapeutics AB has 64,359,795 shares outstanding.

What happened to Stayble Therapeutics AB’s price movement after its last earnings report?

Stayble Therapeutics AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Stayble Therapeutics AB?

Currently, no hedge funds are holding shares in DE:4K4

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Stayble Therapeutics AB

Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.